Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Combined Hormonal Contraceptives Market by Product (Drugs, Devices), by Age Group (15-24 years, 25-34 years, 35-44 years, Above 44 years) and by End User (Hospitals, Household, Clinics): Global Opportunity Analysis and Industry Forecast, 2023-2032

A02598

Pages: NA

Charts: NA

Tables: NA

Combined hormonal contraceptives are used to prevent pregnancies. They are also used in the treatment of acne vulgaris, endometriosis, polycystic ovarian syndrome, and irregular menstrual flow by blocking ovulation. These products are widely used by women of aged between 15 and 49 years.

The factors driving the combined hormonal contraceptives market include increase in adoption of combined hormonal contraceptives products or birth control methods in the developing countries and incidence of polycystic ovary syndrome (PCOS). Moreover, rise in population attaining higher education, need of family planning, and growth in measures to prevent unwanted pregnancy further fuels the market growth. However, health risks associated with the use of contraceptives and lack of social acceptance by people restrict the market. The growth in awareness about contraceptives among people and initiatives taken by government in untapped emerging economies provide significant opportunities for market growth.

Combined hormonal contraceptives market is segmented on the basis of product type, age group, end users, and region. Based on product type, the market is bifurcated into drugs (combined oral contraceptive pills, combined injectable birth control, and combined emergency contraceptive pills) and devices (combined vaginal rings, and combined transdermal patches). On the basis of age group the market is categorized into 1524, 2534, 3544, and above 44 years. By end user, the market is classified into hospitals, household, and clinics. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key players profiled in the report include Actavis Plc., Agile Therapeutics, Inc., Allergan Plc., Bayer AG, Teva Pharmaceutical Industries Ltd., ANI Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., Noven Pharmaceuticals, Inc., Johnson & Johnson, and Mylan Inc.

Key Benefits

  • The study provides an in-depth analysis of the global combined hormonal contraceptives market with current trends and future estimations to elucidate the imminent investment pockets.
  • The report provides information about the current and upcoming trends in the global combined hormonal contraceptives market which helps to determine the prevailing opportunities.
  • Comprehensive analysis of factors that drive and restrict the growth of the geriatric care devices market is provided.
  • Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale are provided.
  • Key market players within the market are profiled in this report and their strategies are analyzed thoroughly, which help understand the competitive outlook of the combined hormonal contraceptives.

 Key Market Segments

  • By Product
    • Drugs
      • Combined Oral Contraceptive Pills
      • Combined Injectable Birth Control
      • Combined Emergency Contraceptive Pills
    • Devices
      • Combined Vaginal Rings
      • Combined Transdermal Patches
  • By Age Group
    • 15-24 years
    • 25-34 years
    • 35-44 years
    • Above 44 years
  • By End User
    • Hospitals
    • Household
    • Clinics
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Teva Pharmaceutical Industries Ltd.
  • Noven Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Actavis Plc.
  • Agile Therapeutics, Inc.
  • Allergan Plc.
  • Mylan Inc.
  • Ortho-McNeil-Janssen Pharmaceuticals, Inc.
  • Bayer AG
  • ANI Pharmaceuticals, Inc.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: COMBINED HORMONAL CONTRACEPTIVES MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Drugs

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

      • 4.2.4. Combined Oral Contraceptive Pills

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Combined Injectable Birth Control

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Combined Emergency Contraceptive Pills

        • 4.2.4.1. Market Size and Forecast

    • 4.3. Devices

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

      • 4.3.4. Combined Vaginal Rings

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Combined Transdermal Patches

        • 4.3.4.1. Market Size and Forecast

  • CHAPTER 5: COMBINED HORMONAL CONTRACEPTIVES MARKET, BY AGE GROUP

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Age Group

    • 5.2. 15-24 Years

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. 25-34 Years

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. 35-44 Years

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Above 44 Years

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: COMBINED HORMONAL CONTRACEPTIVES MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Household

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Clinics

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: COMBINED HORMONAL CONTRACEPTIVES MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Product

      • 7.2.3. Market Size and Forecast, By Age Group

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Combined Hormonal Contraceptives Market

        • 7.2.6.1. Market Size and Forecast, By Product
        • 7.2.6.2. Market Size and Forecast, By Age Group
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Combined Hormonal Contraceptives Market

        • 7.2.7.1. Market Size and Forecast, By Product
        • 7.2.7.2. Market Size and Forecast, By Age Group
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Combined Hormonal Contraceptives Market

        • 7.2.8.1. Market Size and Forecast, By Product
        • 7.2.8.2. Market Size and Forecast, By Age Group
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Product

      • 7.3.3. Market Size and Forecast, By Age Group

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Combined Hormonal Contraceptives Market

        • 7.3.6.1. Market Size and Forecast, By Product
        • 7.3.6.2. Market Size and Forecast, By Age Group
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Combined Hormonal Contraceptives Market

        • 7.3.7.1. Market Size and Forecast, By Product
        • 7.3.7.2. Market Size and Forecast, By Age Group
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Combined Hormonal Contraceptives Market

        • 7.3.8.1. Market Size and Forecast, By Product
        • 7.3.8.2. Market Size and Forecast, By Age Group
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Combined Hormonal Contraceptives Market

        • 7.3.9.1. Market Size and Forecast, By Product
        • 7.3.9.2. Market Size and Forecast, By Age Group
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Combined Hormonal Contraceptives Market

        • 7.3.10.1. Market Size and Forecast, By Product
        • 7.3.10.2. Market Size and Forecast, By Age Group
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Combined Hormonal Contraceptives Market

        • 7.3.11.1. Market Size and Forecast, By Product
        • 7.3.11.2. Market Size and Forecast, By Age Group
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Combined Hormonal Contraceptives Market

        • 7.3.12.1. Market Size and Forecast, By Product
        • 7.3.12.2. Market Size and Forecast, By Age Group
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Product

      • 7.4.3. Market Size and Forecast, By Age Group

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Combined Hormonal Contraceptives Market

        • 7.4.6.1. Market Size and Forecast, By Product
        • 7.4.6.2. Market Size and Forecast, By Age Group
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Combined Hormonal Contraceptives Market

        • 7.4.7.1. Market Size and Forecast, By Product
        • 7.4.7.2. Market Size and Forecast, By Age Group
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Combined Hormonal Contraceptives Market

        • 7.4.8.1. Market Size and Forecast, By Product
        • 7.4.8.2. Market Size and Forecast, By Age Group
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Combined Hormonal Contraceptives Market

        • 7.4.9.1. Market Size and Forecast, By Product
        • 7.4.9.2. Market Size and Forecast, By Age Group
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Combined Hormonal Contraceptives Market

        • 7.4.10.1. Market Size and Forecast, By Product
        • 7.4.10.2. Market Size and Forecast, By Age Group
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Combined Hormonal Contraceptives Market

        • 7.4.11.1. Market Size and Forecast, By Product
        • 7.4.11.2. Market Size and Forecast, By Age Group
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Combined Hormonal Contraceptives Market

        • 7.4.12.1. Market Size and Forecast, By Product
        • 7.4.12.2. Market Size and Forecast, By Age Group
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Combined Hormonal Contraceptives Market

        • 7.4.13.1. Market Size and Forecast, By Product
        • 7.4.13.2. Market Size and Forecast, By Age Group
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Combined Hormonal Contraceptives Market

        • 7.4.14.1. Market Size and Forecast, By Product
        • 7.4.14.2. Market Size and Forecast, By Age Group
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Product

      • 7.5.3. Market Size and Forecast, By Age Group

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Combined Hormonal Contraceptives Market

        • 7.5.6.1. Market Size and Forecast, By Product
        • 7.5.6.2. Market Size and Forecast, By Age Group
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Combined Hormonal Contraceptives Market

        • 7.5.7.1. Market Size and Forecast, By Product
        • 7.5.7.2. Market Size and Forecast, By Age Group
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Combined Hormonal Contraceptives Market

        • 7.5.8.1. Market Size and Forecast, By Product
        • 7.5.8.2. Market Size and Forecast, By Age Group
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Combined Hormonal Contraceptives Market

        • 7.5.9.1. Market Size and Forecast, By Product
        • 7.5.9.2. Market Size and Forecast, By Age Group
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Combined Hormonal Contraceptives Market

        • 7.5.10.1. Market Size and Forecast, By Product
        • 7.5.10.2. Market Size and Forecast, By Age Group
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Combined Hormonal Contraceptives Market

        • 7.5.11.1. Market Size and Forecast, By Product
        • 7.5.11.2. Market Size and Forecast, By Age Group
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Actavis Plc.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Agile Therapeutics, Inc.

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Allergan Plc.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Bayer AG

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Teva Pharmaceutical Industries Ltd.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. ANI Pharmaceuticals, Inc.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Ortho-McNeil-Janssen Pharmaceuticals, Inc.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Noven Pharmaceuticals, Inc.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Johnson And Johnson

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Mylan Inc.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL COMBINED HORMONAL CONTRACEPTIVES MARKET, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL COMBINED HORMONAL CONTRACEPTIVES MARKET FOR DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL COMBINED HORMONAL CONTRACEPTIVES MARKET FOR DEVICES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL COMBINED HORMONAL CONTRACEPTIVES MARKET, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL COMBINED HORMONAL CONTRACEPTIVES MARKET FOR 15-24 YEARS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL COMBINED HORMONAL CONTRACEPTIVES MARKET FOR 25-34 YEARS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL COMBINED HORMONAL CONTRACEPTIVES MARKET FOR 35-44 YEARS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL COMBINED HORMONAL CONTRACEPTIVES MARKET FOR ABOVE 44 YEARS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL COMBINED HORMONAL CONTRACEPTIVES MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL COMBINED HORMONAL CONTRACEPTIVES MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL COMBINED HORMONAL CONTRACEPTIVES MARKET FOR HOUSEHOLD, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL COMBINED HORMONAL CONTRACEPTIVES MARKET FOR CLINICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL COMBINED HORMONAL CONTRACEPTIVES MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA COMBINED HORMONAL CONTRACEPTIVES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. NORTH AMERICA COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 18. U.S. COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 19. U.S. COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 20. U.S. COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 21. CANADA COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 22. CANADA COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 23. CANADA COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 24. MEXICO COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 25. MEXICO COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 26. MEXICO COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 27. EUROPE COMBINED HORMONAL CONTRACEPTIVES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 28. EUROPE COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 31. FRANCE COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 32. FRANCE COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 33. FRANCE COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 34. GERMANY COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 35. GERMANY COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 36. GERMANY COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 37. ITALY COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 38. ITALY COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 39. ITALY COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 40. SPAIN COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 41. SPAIN COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 42. SPAIN COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 43. UK COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 44. UK COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 45. UK COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 46. RUSSIA COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 47. RUSSIA COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 48. RUSSIA COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 49. REST OF EUROPE COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 50. REST OF EUROPE COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 51. REST OF EUROPE COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 52. ASIA-PACIFIC COMBINED HORMONAL CONTRACEPTIVES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 53. ASIA-PACIFIC COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 54. ASIA-PACIFIC COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 56. CHINA COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 57. CHINA COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 58. CHINA COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 59. JAPAN COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 60. JAPAN COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 61. JAPAN COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 62. INDIA COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 63. INDIA COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 64. INDIA COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH KOREA COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 66. SOUTH KOREA COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH KOREA COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 68. AUSTRALIA COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 69. AUSTRALIA COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 70. AUSTRALIA COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 71. THAILAND COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 72. THAILAND COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 73. THAILAND COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 74. MALAYSIA COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 75. MALAYSIA COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 76. MALAYSIA COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 77. INDONESIA COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 78. INDONESIA COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 79. INDONESIA COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 80. REST OF ASIA PACIFIC COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 83. LAMEA COMBINED HORMONAL CONTRACEPTIVES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 84. LAMEA COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 85. LAMEA COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 87. BRAZIL COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 88. BRAZIL COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 89. BRAZIL COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 90. SOUTH AFRICA COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 91. SOUTH AFRICA COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH AFRICA COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 93. SAUDI ARABIA COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 94. SAUDI ARABIA COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 95. SAUDI ARABIA COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 96. UAE COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 97. UAE COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 98. UAE COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 99. ARGENTINA COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 100. ARGENTINA COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 101. ARGENTINA COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 102. REST OF LAMEA COMBINED HORMONAL CONTRACEPTIVES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 103. REST OF LAMEA COMBINED HORMONAL CONTRACEPTIVES, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 104. REST OF LAMEA COMBINED HORMONAL CONTRACEPTIVES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 105. ACTAVIS PLC.: KEY EXECUTIVES
  • TABLE 106. ACTAVIS PLC.: COMPANY SNAPSHOT
  • TABLE 107. ACTAVIS PLC.: OPERATING SEGMENTS
  • TABLE 108. ACTAVIS PLC.: PRODUCT PORTFOLIO
  • TABLE 109. ACTAVIS PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110. AGILE THERAPEUTICS, INC.: KEY EXECUTIVES
  • TABLE 111. AGILE THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 112. AGILE THERAPEUTICS, INC.: OPERATING SEGMENTS
  • TABLE 113. AGILE THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 114. AGILE THERAPEUTICS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. ALLERGAN PLC.: KEY EXECUTIVES
  • TABLE 116. ALLERGAN PLC.: COMPANY SNAPSHOT
  • TABLE 117. ALLERGAN PLC.: OPERATING SEGMENTS
  • TABLE 118. ALLERGAN PLC.: PRODUCT PORTFOLIO
  • TABLE 119. ALLERGAN PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 120. BAYER AG: KEY EXECUTIVES
  • TABLE 121. BAYER AG: COMPANY SNAPSHOT
  • TABLE 122. BAYER AG: OPERATING SEGMENTS
  • TABLE 123. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 124. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 125. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 126. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 127. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 128. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 129. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 130. ANI PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 131. ANI PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 132. ANI PHARMACEUTICALS, INC.: OPERATING SEGMENTS
  • TABLE 133. ANI PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 134. ANI PHARMACEUTICALS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 135. ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 136. ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 137. ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC.: OPERATING SEGMENTS
  • TABLE 138. ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 139. ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 140. NOVEN PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 141. NOVEN PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 142. NOVEN PHARMACEUTICALS, INC.: OPERATING SEGMENTS
  • TABLE 143. NOVEN PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 144. NOVEN PHARMACEUTICALS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 145. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 146. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 147. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 148. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 149. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150. MYLAN INC.: KEY EXECUTIVES
  • TABLE 151. MYLAN INC.: COMPANY SNAPSHOT
  • TABLE 152. MYLAN INC.: OPERATING SEGMENTS
  • TABLE 153. MYLAN INC.: PRODUCT PORTFOLIO
  • TABLE 154. MYLAN INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL COMBINED HORMONAL CONTRACEPTIVES MARKET SEGMENTATION
  • FIGURE 2. GLOBAL COMBINED HORMONAL CONTRACEPTIVES MARKET
  • FIGURE 3. SEGMENTATION COMBINED HORMONAL CONTRACEPTIVES MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN COMBINED HORMONAL CONTRACEPTIVES MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCOMBINED HORMONAL CONTRACEPTIVES MARKET
  • FIGURE 11. COMBINED HORMONAL CONTRACEPTIVES MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. COMBINED HORMONAL CONTRACEPTIVES MARKET FOR DRUGS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. COMBINED HORMONAL CONTRACEPTIVES MARKET FOR DEVICES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. COMBINED HORMONAL CONTRACEPTIVES MARKET SEGMENTATION, BY BY AGE GROUP
  • FIGURE 15. COMBINED HORMONAL CONTRACEPTIVES MARKET FOR 15-24 YEARS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. COMBINED HORMONAL CONTRACEPTIVES MARKET FOR 25-34 YEARS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. COMBINED HORMONAL CONTRACEPTIVES MARKET FOR 35-44 YEARS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. COMBINED HORMONAL CONTRACEPTIVES MARKET FOR ABOVE 44 YEARS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. COMBINED HORMONAL CONTRACEPTIVES MARKET SEGMENTATION, BY BY END USER
  • FIGURE 20. COMBINED HORMONAL CONTRACEPTIVES MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. COMBINED HORMONAL CONTRACEPTIVES MARKET FOR HOUSEHOLD, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. COMBINED HORMONAL CONTRACEPTIVES MARKET FOR CLINICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 24. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 25. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 26. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 27. COMPETITIVE DASHBOARD
  • FIGURE 28. COMPETITIVE HEATMAP: COMBINED HORMONAL CONTRACEPTIVES MARKET
  • FIGURE 29. TOP PLAYER POSITIONING, 2024
  • FIGURE 30. ACTAVIS PLC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 31. ACTAVIS PLC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 32. ACTAVIS PLC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 33. AGILE THERAPEUTICS, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. AGILE THERAPEUTICS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. AGILE THERAPEUTICS, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. ALLERGAN PLC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. ALLERGAN PLC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. ALLERGAN PLC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. BAYER AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. BAYER AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. BAYER AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. ANI PHARMACEUTICALS, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. ANI PHARMACEUTICALS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. ANI PHARMACEUTICALS, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. NOVEN PHARMACEUTICALS, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. NOVEN PHARMACEUTICALS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. NOVEN PHARMACEUTICALS, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. JOHNSON AND JOHNSON: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 57. MYLAN INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 58. MYLAN INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 59. MYLAN INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Combined Hormonal Contraceptives Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved